safinamide has been researched along with glutamic acid in 6 studies
| Studies (safinamide) | Trials (safinamide) | Recent Studies (post-2010) (safinamide) | Studies (glutamic acid) | Trials (glutamic acid) | Recent Studies (post-2010) (glutamic acid) |
|---|---|---|---|---|---|
| 199 | 29 | 159 | 41,757 | 452 | 12,876 |
| Protein | Taxonomy | safinamide (IC50) | glutamic acid (IC50) |
|---|---|---|---|
| Chain A, GLUTAMATE RECEPTOR SUBUNIT 2 | Rattus norvegicus (Norway rat) | 0.821 | |
| Chain A, Glutamate Receptor Subunit 2 | Rattus norvegicus (Norway rat) | 0.821 | |
| Chain B, Glutamate Receptor Subunit 2 | Rattus norvegicus (Norway rat) | 0.821 | |
| Metabotropic glutamate receptor 8 | Homo sapiens (human) | 0.0057 | |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | 0.07 | |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | 0.5885 | |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | 0.5885 | |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | 0.5885 | |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | 0.5885 | |
| Glutamate receptor ionotropic, kainate 1 | Rattus norvegicus (Norway rat) | 0.38 | |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, kainate 2 | Rattus norvegicus (Norway rat) | 0.38 | |
| Glutamate receptor 1 | Homo sapiens (human) | 0.613 | |
| Glutamate receptor 2 | Homo sapiens (human) | 0.613 | |
| Glutamate receptor 3 | Homo sapiens (human) | 0.613 | |
| Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | 0.38 | |
| Excitatory amino acid transporter 1 | Homo sapiens (human) | 207 | |
| Glutamate receptor 4 | Homo sapiens (human) | 0.613 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, kainate 4 | Rattus norvegicus (Norway rat) | 0.38 | |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, kainate 5 | Rattus norvegicus (Norway rat) | 0.38 | |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | 0.07 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.1533 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.1533 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caccia, C; Cervini, MA; Faravelli, L; Fariello, RG; Fornaretto, MG; Lamberti, E; Maj, R; Mancinelli, E; Mazzanti, M; Pevarello, P; Salvati, P; Skeen, GA; Varasi, M; White, HS; Wolf, HH | 1 |
| Arnold, G; Bonuccelli, U; Cattaneo, C; Fariello, RG; Kwiecinski, H; Onofrj, M; Sala, P; Stocchi, F; Szczudlik, A; Thomas, A; Van Dijk, A | 1 |
| Brugnoli, A; Caccia, C; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sardina, M; Vailati, S | 1 |
| Bonizzoni, E; Cattaneo, C; Jost, WH | 1 |
| Brugnoli, A; Caccia, C; Keywood, C; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Vailati, S | 1 |
| Bastioli, G; Caccia, C; Calabresi, P; Cardinale, A; Ghiglieri, V; Keywood, C; Mazzocchetti, P; Melloni, E; Mosci, P; Padoani, G; Picconi, B; Sciaccaluga, M; Tozzi, A; Vailati, S | 1 |
2 trial(s) available for safinamide and glutamic acid
| Article | Year |
|---|---|
Improvement of motor function in early Parkinson disease by safinamide.
Topics: Adult; Aged; Alanine; Antiparkinson Agents; Benzylamines; Calcium Channel Blockers; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Gastrointestinal Diseases; Glutamic Acid; Humans; Male; Middle Aged; Motor Activity; Neuroprotective Agents; Parkinson Disease; Sodium Channel Blockers; Treatment Outcome | 2004 |
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Severity of Illness Index | 2020 |
4 other study(ies) available for safinamide and glutamic acid
| Article | Year |
|---|---|
Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound.
Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Brain; Calcium Channels; Glutamic Acid; Male; Membranes; Mice; Neurons; Patch-Clamp Techniques; Potassium Channels; Potassium Chloride; Rats; Rats, Wistar; Veratrine | 1999 |
Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.
Topics: Alanine; Animals; Basal Ganglia; Benzylamines; gamma-Aminobutyric Acid; Glutamic Acid; Hippocampus; Male; Neurons; Rats; Rats, Sprague-Dawley | 2018 |
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2020 |
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; Glutamic Acid; Levodopa; Male; Nerve Net; Organ Culture Techniques; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2020 |